Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies

Abstract

Methods are provided for treating a lymphoproliferative malignancy to a patient in need of such treatment, comprising administering to the patient an effective amount of compound A as described herein.

What is claimed is: 
     
         1 . A method of treating a lymphoproliferative malignancy in a human patient in need of such treatment, comprising administering to the patient an effective amount of Compound A 
       
         
           
           
               
               
           
         
       
       or a tautomer, zwitterion, or pharmaceutically salt thereof, wherein the Compound A or pharmaceutically acceptable salt thereof is administered at a continuous once daily dose. 
     
     
         2 . The method of  claim 1 , wherein the Compound A or pharmaceutically acceptable salt thereof is administered at a continuous once daily dose in capsule form of about 600 mg. 
     
     
         3 . The method of  claim 1 , wherein the Compound A or pharmaceutically acceptable salt thereof is administered at a continuous once daily dose in tablet form of about 200 to about 600 mg. 
     
     
         4 . The method of  claim 1 , wherein the Compound A or pharmaceutically acceptable salt thereof is administered at a continuous once daily dose in tablet form of about 400 mg. 
     
     
         5 . The method of any of  claims 1 - 4 , wherein the patient fasts prior to the administration. 
     
     
         6 . The method of any of  claims 1 - 5 , wherein the lymphoproliferative malignancy is chronic lymphocytic leukemia/small lymphocytic lymphoma, Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, follicular lymphoma, or diffuse large B-cell lymphoma or transformed lymphoma. 
     
     
         7 . The method of any of  claims 1 - 6 , wherein the lymphoproliferative malignancy is relapsed or refractory. 
     
     
         8 . The method of any of  claims 1 - 7 , wherein the effective amount produces at least one therapeutic effect selected from the group consisting of reduction in size of a tumor, reduction in metastasis, complete remission, partial remission, stable disease, increase in overall response rate, or a pathologic complete response.